Cadence Pharmaceuticals News

I believe that Ofirmev, Cadence's intravenous formulation of acetaminophen, has significant potential as an alternative to intravenous opioids and non-steroidal anti-inflammatories analgesics that are used broadly in the hospital.

HONG KONG -- -- 05/31/12 -- Today, www.BollingerReport.com introduced featured coverage of Cadence Pharmaceuticals, Inc.

Shares of Cadence Pharmaceuticals traded down 13.89% during mid-day trading on Friday, hitting $3.10. Cadence Pharmaceuticals has a 52 week low of $3.25 and a 52 week high of $10.00. The company's market cap is $265.1 million.

Cadence Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss First Quarter 2012 Financial Results on May 3, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc.